- Motley Fool•4 days ago
Belviq's weak sales weighed heavily on Arena's stock last year.
- Zacks•7 days ago
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
- Zacks•8 days ago
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.
ARNA: Summary for Arena Pharmaceuticals, Inc. - Yahoo Finance
Arena Pharmaceuticals, Inc. (ARNA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||1.37 x 1000|
|Ask||1.53 x 1600|
|Day's range||1.41 - 1.48|
|52-week range||1.32 - 2.16|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-3.74|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|